These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28130762)

  • 1. New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
    Cortese S; D'Acunto G; Konofal E; Masi G; Vitiello B
    CNS Drugs; 2017 Feb; 31(2):149-160. PubMed ID: 28130762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above.
    Childress A; Ponce De Leon B; Owens M
    Expert Opin Drug Deliv; 2018 Dec; 15(12):1263-1270. PubMed ID: 30404549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
    Sugrue D; Bogner R; Ehret MJ
    Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults.
    Childress A; Stark JG; McMahen R; Engelking D; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):151-159. PubMed ID: 28544581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD.
    Childress A; Sallee FR
    Expert Rev Neurother; 2013 Sep; 13(9):979-88. PubMed ID: 24053342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
    Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
    Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.
    Teuscher NS; Sikes CR; McMahen R; Engelking D
    J Clin Psychopharmacol; 2018 Oct; 38(5):467-474. PubMed ID: 30119076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
    Weisler RH; Stark JG; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QuilliChew ER--extended-release chewable methylphenidate tablets.
    Med Lett Drugs Ther; 2016 May; 58(1495):68-9. PubMed ID: 27192619
    [No Abstract]   [Full Text] [Related]  

  • 16. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder.
    Frölich J; Banaschewski T; Döpfner M; Görtz-Dorten A
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1169-83. PubMed ID: 24856438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study.
    Auiler JF; Liu K; Lynch JM; Gelotte CK
    Curr Med Res Opin; 2002; 18(5):311-6. PubMed ID: 12240794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder.
    Teuscher NS; Adjei A; Findling RL; Greenhill LL; Kupper RJ; Wigal S
    Drug Des Devel Ther; 2015; 9():2767-75. PubMed ID: 26060393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole.
    Abbas R; Childress AC; Nagraj P; Rolke R; Berry SA; Palumbo DR
    Clin Ther; 2018 May; 40(5):733-740. PubMed ID: 29703430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.